Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme -- Ignore unavailable to you. Want to Upgrade?

To: Nanda who wrote (2331)	6/4/1998 10:41:00 AM
From: MoneyMade	Respond to of 8798

RMGG! The comeback kid... To: Vicki G (96 ) From: Gator Thursday, Jun 4 1998 8:35AM ET Reply # of 98 Info from the Pennystocks site (posted prior to news release): Posted by MikeT on June 03, 1998 at 19:15:40: RMMG Follow Up I spoke with public relations spokesperson Bob Bell about RMGG. There is more going on than I had originally anticipated. There are 20 million shares outstanding. Approximately 10 million of that is the float with 5 million of them restricted and will remain so long term. The remaining 5 million are being held by management and other investors with no intention of selling in the near future. Wednesday morning, June 3rd, RMGG and government officials from both Canada and China held a ceremonial signing of the aquisition of Fuzhou Fujiang Drugs Co., Ltd. Details of this will be released shortly, at which point I will post that release for you to read. Litchfield Continential, who owns Biofarm S.A., is supplying RMGG the financing for this aquisition. Fuzhou Fujiang has established its own sales and distribution network of 131 outlets in key Chinese business centers and employs 35 people. Currently, RMGG and Biofarm S.A., a European pharmaceutical company who manufacture over 200 pharmaceutical products in Europe, have identified several drugs which Biofarm presently produces that are of interest to the China market. It is the intention of both companies to persue the feasibility of manufacturing and distribution of these pharmaceutical products in China. RMGG will launch two new products in China in late June, "Heavenly Slices" and "Ginseng in Honey". These products will be distributed by 2200 supermarkets in Shanghai. RMGG's main thrust is in China but they are currently seeking registration in 20 European countries. To date they have obtained registration in countries such as Lithuania, Italy, Belgium, Romania, Estonia, the UK, Latvia,and Bangladesh. It should be noted that RMGG received official Trademark Registration in China for the name "Rocky Mountain Ginseng" and logo which gives them the exclusive right to use this trademark. This is important as the Chinese associate the Rocky Mountains with Canada and the source of high quality products. In North America and Europe RMGG has successfully registered the trademark "Gold Root". There are 1.2 billion people in China and ginseng is considered among the highest gifts one person can give to another. Ginseng is a large part of the Chinese culture and the "People's Daily", a Chinese newspaper, reported an annual shortfall of 1,000 - 2,000 tonnes of ginseng in China annually. American ginseng is considered to be the best ginseng by the Chinese. The purchase of Fuzhou Fujiang Drugs Co., Ltd. will not be a joint effort, but rather provide RMGG with 100% ownership and give RMGG the necessary licences to export, import and manufacture in China. RMGG will be the only American ginseng company to own a Chinese drug company. 1997 audited results and 1998 first quarter unaudited results should be released this month. In a nutshell, this company has broken ground in a country that has been closed to most outside influences. It is only because of the extreme importance of ginseng to the people of China this opportunity exists. RMGG can provide a precious resource to the Chinese, and do so unchallenged. As in every case, if you supply what people want, there is money to be made. RMGG is at the beginning of a long road. To enter now at the ground floor is certainly an opportunity to be considered. The company has a long way to go, but at .16 a share, it is certainly a strong temptation. Michael Thayres Public Relations: Bob Bell 1-604-420-0095 MoneyMade